http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021046233-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4aba5130b481ea5be1710d495eac3cad |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-0402 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2020-09-03^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f75a53ee735a1411b8ce3aa179afbb5b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d42ff08ebb9aafc48a00d34a7d17af75 |
| publicationDate | 2021-03-11^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2021046233-A1 |
| titleOfInvention | Chelate-containing psma inhibitors |
| abstract | Provided herein are PMSA-binding molecules comprising a albumin-binding moiety and a chelating agent optionally chelating a therapeutic radioisotope or a PET-active, SPECT-active, or MR I -active radioisotope. The compound of Formula (II*) (and its therapeutically acceptable salt) is representative. Also provided are compositions including a compound of the disclosure together with a pharmaceutically acceptable carrier, methods for imaging prostate cancer cells with radioisotope-chelated compounds of the disclosure, and methods of synthesizing the compounds. |
| priorityDate | 2019-09-03^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 132 of 132.